...
首页> 外文期刊>Scandinavian journal of urology and nephrology >Effect of hemodialysis on serum complexed prostate-specific antigen levels.
【24h】

Effect of hemodialysis on serum complexed prostate-specific antigen levels.

机译:血液透析对血清复合前列腺特异性抗原水平的影响。

获取原文
获取原文并翻译 | 示例

摘要

OBJECTIVE: The measurement of prostate-specific antigen (PSA) is a useful tool in the screening and follow-up of prostate cancer, but its diagnostic validity is uncertain in hemodialysis patients. The aim of this study was to evaluate the effects of hemodialysis on serum complexed PSA (cPSA) levels. MATERIAL AND METHODS: A total of 36 men (mean age 62.54+/-8.20 years) with end-stage renal disease were enrolled in a prospective study. Serum total PSA (tPSA), free PSA (fPSA) and cPSA, and hematocrit levels were measured before and immediately after dialysis using low-flux membranes in the serum and in the dialysis ultrafiltrate. RESULTS: After hemodialysis, cPSA, fPSA and the fPSA:tPSA ratio increased significantly (p<0.05). However, there was no significant increase in tPSA. fPSA, cPSA and tPSA were not detected in ultrafiltrate. Hematocrit levels increased significantly (p<0.0001) due to hemoconcentration. Of patients with initial serum tPSA and cPSA values and fPSA:tPSA ratios below the cut-off values, none had a post-hemodialysis value greater than the cut-off point. There were weak correlation between the difference in values after and before hemodialysis of hematocrit and cPSA (p=0.035), and between the percentage change in levels before and after hemodialysis of hematocrit and cPSA (p=0.041). CONCLUSIONS: Hemodialysis induced elevations in all forms of PSA, but tPSA was the least affected form. cPSA did not show any diagnostic superiority over other forms of PSA. Thus, serum tPSA remains a reliable parameter for follow-up of prostate cancer in uremic patients receiving long-term dialysis. However, further research is needed to explain the pathophysiology of alterations in the concentrations of different forms of PSA.
机译:目的:检测前列腺特异性抗原(PSA)是筛查和随访前列腺癌的有用工具,但其在血液透析患者中​​的诊断有效性尚不确定。这项研究的目的是评估血液透析对血清复合PSA(cPSA)水平的影响。材料与方法:前瞻性研究共纳入了36名终末期肾脏疾病的男性(平均年龄62.54 +/- 8.20岁)。在透析前和透析后立即使用血清和超滤液中的低通量膜测量血清总PSA(tPSA),游离PSA(fPSA)和cPSA,以及血细胞比容水平。结果:血液透析后,cPSA,fPSA和fPSA:tPSA比值显着增加(p <0.05)。但是,tPSA没有明显增加。在超滤液中未检测到fPSA,cPSA和tPSA。由于血液浓缩,血细胞比容水平显着增加(p <0.0001)。在初始血清tPSA和cPSA值以及fPSA:tPSA比低于临界值的患者中,没有一个患者的血液透析后值大于临界值。血细胞比容和cPSA血液透析前后的值差异与血细胞比容和cPSA血液透析前后水平的百分比变化之间弱相关(p = 0.041)。结论:血液透析引起各种形式的PSA升高,但tPSA受影响最小。与其他形式的PSA相比,cPSA没有显示出任何诊断优势。因此,血清tPSA仍然是接受长期透析的尿毒症患者前列腺癌随访的可靠参数。然而,需要进一步的研究来解释不同形式的PSA浓度变化的病理生理学。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号